Table 2 The trend of prevalence of AMR during 2008 to 2015
| Type of AMR | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Methicillin-resistant Staphylococcus aureus | 10.46% | 10.01% | 9.43% | 8.77% | 8.06% | 7.48% | 6.91% | 6.64% |
| Vancomycin-resistant Enterococci | 0.03% | 0.05% | 0.05% | 0.03% | 0.02% | 0.02% | 0.02% | 0.02% |
|
Penicillin-resistant Streptococcus pneumoniae | 1.31% | 1.29% | 1.38% | 1.15% | 0.89% | 0.79% | 0.69% | 0.64% |
|
Multidrug-resistant Pseudomonas aeruginosa | 0.23% | 0.18% | 0.18% | 0.18% | 0.14% | 0.12% | 0.09% | 0.07% |
|
Multidrug-resistant Acinetobacter spp. | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Carbapenem-resistant Enterobacteriaceae | ND | ND | ND | ND | ND | ND | 0.49% | 0.36% |
|
Carbapenem-resistant Pseudomonas aeruginosa | 1.45% | 1.30% | 1.26% | 1.26% | 1.09% | 0.98% | 0.88% | 0.84% |
| 3rd generation cephalosporin-resistant Klebsiella pneumoniae | 0.17% | 0.18% | 0.19% | 0.24% | 0.24% | 0.23% | 0.33% | 0.32% |
| 3rd generation cephalosporin-resistant Escherichia coli | 0.62% | 0.70% | 0.86% | 1.14% | 1.30% | 1.40% | 1.82% | 1.99% |
|
Fluoroquinolone-resistant Escherichia coli | 1.79% | 1.88% | 2.15% | 2.52% | 2.87% | 3.12% | 3.35% | 3.70% |
| Patients for whom samples were submitted | 930,861 | 1,056,555 | 1,069,216 | 1,309,993 | 1,453,969 | 1,584,041 | 1,747,538 | 2,551,541 |
